Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
Frontiers in Chemistry
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-28
DOI
10.3389/fchem.2020.00407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nutrient Regulation of Signaling & Transcription
- (2019) Gerald W. Hart JOURNAL OF BIOLOGICAL CHEMISTRY
- Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions
- (2019) Jianping Liu et al. Small
- A Binding Site Hotspot Map of the FKBP12–Rapamycin–FRB Ternary Complex by Photoaffinity Labeling and Mass Spectrometry-Based Proteomics
- (2019) Hope A. Flaxman et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease
- (2019) Wendi Teng et al. JOURNAL OF CONTROLLED RELEASE
- Lipotoxic Hepatocyte‐Derived Exosomal miR‐192‐5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in NAFLD
- (2019) Xiao‐Lin Liu et al. HEPATOLOGY
- Smart cancer nanomedicine
- (2019) Roy van der Meel et al. Nature Nanotechnology
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
- (2019) Gordon I. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy
- (2018) Wan Zhou et al. CELL BIOLOGY INTERNATIONAL
- DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease
- (2018) Hanqing Chen et al. HEPATOLOGY
- Future therapy for non-alcoholic fatty liver disease
- (2018) Danny Issa et al. LIVER INTERNATIONAL
- Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target
- (2018) Dabin Liu et al. Science Translational Medicine
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice
- (2018) Chad N. Brocker et al. JOURNAL OF LIPID RESEARCH
- Polyurethane Nanoparticle-Loaded Fenofibrate Exerts Inhibitory Effects on Nonalcoholic Fatty Liver Disease in Mice
- (2018) Yi-ni Cao et al. MOLECULAR PHARMACEUTICS
- Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis
- (2018) Xu-Yun Zhao et al. Nature Communications
- Lipid mediators of liver injury in nonalcoholic fatty liver disease
- (2018) Suthat Liangpunsakul et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- mTOR as a central hub of nutrient signalling and cell growth
- (2018) Joungmok Kim et al. NATURE CELL BIOLOGY
- Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
- (2018) Yao Yu et al. Advanced Science
- SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology
- (2017) Hitoshi Shimano et al. Nature Reviews Endocrinology
- Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study
- (2017) Janet Bee et al. THORAX
- Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
- (2017) Ahad Eshraghian WORLD JOURNAL OF GASTROENTEROLOGY
- PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
- (2016) Jung Soo Suk et al. ADVANCED DRUG DELIVERY REVIEWS
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- Encapsulation and Controlled Release of Rapamycin from Polycaprolactone Nanoparticles Prepared by Membrane Micromixing Combined with Antisolvent Precipitation
- (2016) Rahimah Othman et al. LANGMUIR
- Co-delivery of doxorubicin and quercetin via mPEG–PLGA copolymer assembly for synergistic anti-tumor efficacy and reducing cardio-toxicity
- (2016) Waseem Akhtar Qureshi et al. Science Bulletin
- Pathological Features of Fatty Liver Disease
- (2014) Matthew M. Yeh et al. GASTROENTEROLOGY
- Nanopharmaceuticals (part 1): products on the market
- (2014) Volkmar Weissig et al. International Journal of Nanomedicine
- Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
- (2013) Yuki Kawano et al. JOURNAL OF GASTROENTEROLOGY
- Epidemiology of alcoholic and nonalcoholic fatty liver disease in China
- (2013) Jian-Gao Fan JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice
- (2013) Chih-Wen Lin et al. JOURNAL OF HEPATOLOGY
- Rapamycin encapsulated in dual-responsive micelles for cancer therapy
- (2012) Yi-Chun Chen et al. BIOMATERIALS
- Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles
- (2011) Hai Wang et al. BIOMATERIALS
- Pathology of nonalcoholic fatty liver disease
- (2010) Elizabeth M. Brunt Nature Reviews Gastroenterology & Hepatology
- The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats
- (2007) Tatsuhiro Ishida et al. JOURNAL OF CONTROLLED RELEASE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now